Emerging Treatments in HIV

Feature Article

HIV Prevention Progress: Effective and Promising Tools on Display at AIDS 2016

HIV Prevention Progress: Effective and Promising Tools on Display at AIDS 2016

Effective and promising tools on display at AIDS 2016 for HIV prevention progress.

The relative risk for healthcare-associated infections has decreased in the last 15 years due to improvements in awareness of risk associated with devices, infection control, and evidence-based practice regarding use of devices.

Latest News

Investigational 2-Drug HIV Regimen Showing Promise

Investigational 2-Drug HIV Regimen Showing Promise

Investigational combination of a once-daily 2-drug regimen of dolutegravir plus rilpivirine may be as effective as a 3- or 4-drug current antiretroviral regimen in HIV-1-infected patients.

Multiple Viral Load Value Testing May Better Inform HIV Transmission Potential

Multiple Viral Load Value Testing May Better Inform HIV Transmission Potential

Viral loads can fluctuate over time depending on patients' access and response to HIV treatment, their medication adherence behavior, and care status.

Potential New Drug Option for Treatment-Naïve HIV-1 Patients

Potential New Drug Option for Treatment-Naïve HIV-1 Patients

The once-daily dosing doravirine appears to have similar efficacy and to be non-inferior to once-daily ritonavir-boosted darunavir (DRV+r) on a background of 2 NRTIs in HIV-1 treatment-naïve adults.

Investigational HIV Monoclonal Antibody Effective in Multiple Drug Resistant HIV-1

Investigational HIV Monoclonal Antibody Effective in Multiple Drug Resistant HIV-1

New phase 3 results were reported from a single arm, multicenter study evaluating the safety and effectiveness of ibalizumab in patients infected with multi-drug resistant HIV-1.

Stribild HIV Post-Exposure Prophylaxis Brings Higher Completion Rate

Stribild HIV Post-Exposure Prophylaxis Brings Higher Completion Rate

HIV PEP preferred regimen Stribild seems to be a good option for immunocompetent people without HIV infection due to the ease of use and tolerable adverse effect profile.

Trends in Cancer That Can Complicate HIV Management

Trends in Cancer That Can Complicate HIV Management

Cancer prevention efforts for patients with HIV should focus on smoking cessation and appropriate screening based on recommendations for the general population.

FDA Green Lights Odefsey for Treating HIV-1

FDA Green Lights Odefsey for Treating HIV-1

Combining emtricitabine and tenofovir alafenamide (Gilead Sciences) and rilpivirine (Janssen Sciences), Odefsey is Gilead's second tenofovir alafenamide-based regimen to receive FDA approval.

Drop-to-Drop Variation Noted With Fingerprick Blood

Drop-to-Drop Variation Noted With Fingerprick Blood

Authors say variation in blood analytes holds implications for point-of-care testing.

Combination HIV Antiretroviral Promising To Rid Body of HIV For Months

Combination HIV Antiretroviral Promising To Rid Body of HIV For Months

The URMC-099 compound combined with antiretroviral therapy significantly reduced HIV levels.

Rifamycin-ART, Other Medication Dosing Errors Noted With TB Therapy

Rifamycin-ART, Other Medication Dosing Errors Noted With TB Therapy

More than half of study patients had at least one medication error linked to antituberculosis therapy.

Sign Up for Free e-newsletters